Samsung’s latest phones, the Galaxy S9 and S9+, will incorporate a new digital health app that will track users' blood pressure and stress level while helping researchers collect data. Seoul-based Samsung Electronics teamed up with the University of California San Fransisco to develop the research app, called My BP Lab.
It looks like a simple fire alarm, but instead of detecting smoke the Kardian Contactless Health Monitoring System is designed to detect falls.
The UK's National Health Service is putting out the call for more mobile health apps for its NHS Apps Library, and has chosen an agency to certify those apps. The library now features 46 mHealth apps - only one of which has passed muster.
Treatment with Novartis’ Ultibro Breezhaler significantly boosted lung and cardiac function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation, trial findings show.
One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of many cancers.
Siemens AG has announced a plan for its Siemens Healthineers business to go public in the first half of the year, according to a company statement. It’s not the first time the German medical imaging and diagnostic business has made its intentions to file an IPO known, but perhaps the company is betting on a more receptive audience in the current market.
Pfizer Inc. (NYSE: PFE) reported financial results for fourthquarter and full-year 2017 and provided 2018 financial guidance.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.
Johnson & Johnson today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth quarter of 2016. Operational sales results increased 9.4% and the positive impact of currency was 2.1%. Domestic sales increased 9.8%. International sales increased 13.5%, reflecting operational growth of 9.0% and a positive currency impact of 4.5%.
GSK delivers improvements in sales, margins and cash flow in 2017:Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.